key: cord-0893341-gtc82zr1
authors: Pillay, J.; Rahman, S.; Guitard, S.; Wingert, A.; Hartling, L.
title: Risk factors and preventive interventions for post Covid-19 condition: systematic reviews
date: 2022-03-25
journal: nan
DOI: 10.1101/2022.03.25.22272949
sha: f20c34d92eab16589e6a1524631ea5794386ed00
doc_id: 893341
cord_uid: gtc82zr1

Background: The Covid-19 outbreak has presented many challenges to governments and healthcare systems, including observations of symptoms that persist beyond acute infection labelled as post Covid-19 condition. Objectives: To systematically identify and synthesize evidence around pre-existing and clinical risk factors for post Covid-19 condition (occurring [≥]12 weeks after positive test/symptom onset) (KQ1), and interventions during the acute and post-acute phases of the illness that could potentially prevent post Covid-19 condition (KQ2). Methods: We searched Medline and Embase (Jan 2021-Aug 12 2021 [KQ1], and Jan 2020-Jul 28, 2021 [KQ2]), Clinicaltrials.gov, organizational websites, and reference lists of included studies and relevant systematic reviews. Two investigators independently reviewed abstracts and full-text articles against a priori inclusion criteria, and disagreements were resolved through discussion or by consulting a third reviewer. One investigator abstracted data and assessed risk of bias using design-specific criteria, and a second investigator checked data abstraction and assessments for completeness and accuracy. Meta-analysis was performed when there was sufficient clinical and methodological similarity in an exposure-outcome comparison, based on prespecified variables. We assessed the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluation approach (GRADE). A relative effect/association of 0.75-1.49 was considered as little-to-no, whereas 0.50-0.74/1.5-1.99 was small-to-moderate and <0.50/[≥]2.00 was large for fewer/benefit or more/harm, respectively Results: From 4,672 (KQ1) and 3,781 (KQ2) citations we included 17 and 18 studies, though 4 studies were included for both KQs. We found small-to-moderate associations between female sex and higher non-recovery, fatigue, and dyspnea (moderate certainty). Severe or critical acute-phase Covid-19 severity (versus not) has probably (moderate certainty) a large association with increased cognitive impairment, a small-to-moderate association with more non-recovery, and a little-to-no association with dyspnea. There may be (low certainty) large associations between hospitalization during the acute illness and increased non-recovery, increased dyspnea, and reduced return to work. There may be small-to-moderate associations between several other risk factors and post Covid-19 condition outcomes, including age [≥]60 versus <60 (functional incapacity), non-White people (lower return to work), children age >6 versus <2 years (non-recovery), having [≥]1 versus no comorbidities (non-recovery), chronic pulmonary disease (fatigue), rheumatologic disorder (depression/anxiety), and chronic obstructive pulmonary disease or hypertension (cognitive impairment). Several other risk factors had low certainty for little-to-no association with one or more outcomes (e.g. diabetes, cardiovascular disease) or very low certainty. Interventions to prevent post Covid-19 condition included medications (standard and traditional/ayurvedic), stem cell therapy, rehabilitation or similar therapies, and screening/referrals at either acute phase (symptom onset to 4 weeks) or early post-acute phase (4-8 week), with short (12-16 weeks) or longer (>16 weeks) follow-up for outcomes. We are very uncertain about the effects of preventive interventions, mainly due to risk of bias, inconsistency/lack of consistency (single studies), and in some cases imprecision. Conclusions: Guidelines in relation to surveillance, screening services, and other services such as access to sickness and disability benefits, might need to focus on females and those with previously severe Covid-19 illness. Interventions targeting fatigue, dyspnea, and cognitive impairment (especially in those who had severe Covid-19) may be good to prioritize for development and evaluation to provide evidence on their effects. Inputs from patients and primary care providers should be taken into account when developing new care pathways and some tailoring to individual needs will likely be paramount. Continuous assessment of the rapidly emerging evidence is important to better shape our understanding as the body of evidence grows. Sufficiently powered prospective trials of preventive interventions are warranted. PROSPERO registration: CRD42021270354

We undertook two systematic reviews following a pre-defined, registered protocol (CRD42021270354) (23) . The reviews are reported following Preferred Reporting Items for Systematic Reviews and Meta-analyses (24, 25) . During protocol development, a working group comprised of members of our research team, representatives from the Public Health Agency of Canada (PHAC) and the Canadian Agency for Drugs and Technologies in Health (CADTH), and clinical experts was formed to refine the review questions and PICOTS components (population, intervention(s) or exposure(s), comparator(s), outcome(s), timing, setting, and study design). The following KQs were determined to be test or symptom onset.

The population of interest for KQ1 included people of any age in the general population (with/without previous Covid- 19) or those with Covid-19. For KQ2, we included people of any age in the acute (0-4 weeks since a positive test/symptom onset) or the post-acute (4-8 weeks) phase of Covid-19; studies could have ≤20% of participants at 9-12 weeks post-Covid. After the protocol development but before data extraction, it was decided by the working group to exclude studies where a majority of the participants had been admitted to an intensive care unit (ICU) during the acute phase, because of the presumed similarity and overlap with post-ICU syndrome for which there are existing treatment pathways and guidelines.

For KQ1, we were interested in pre-existing risk factors (e.g., demographic variables, BMI, specific chronic conditions affecting a relatively large population and found to have an effect on Covid-19 severity (26) , Covid-19 vaccination status, etc.) and clinical risk factors arising during acute phase of Covid-19 (e.g., presence of dyspnea, number of symptoms/symptom severity, need for hospitalization or . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 25, 2022. ;  https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint ICU admission, etc.) (27) . We defined the comparator/control as people without the exposure of interest (e.g., male versus female, people without diabetes, etc.) or with different levels of the exposure (e.g., different age group or BMI category). For KQ2, we included any potentially preventive intervention that started before 8 weeks after a positive Covid-19 test/symptom onset (in ≥80% of study participants). The comparator was usual medical care (e.g., supportive care for acute ; we included studies with no comparator if there were no other studies with a comparator for the intervention.

The outcomes of interest were selected by a rating approach (28) . Groups of clinical experts, policy makers, and patients were asked to rate the importance of each proposed outcome in terms of how important the effect of a risk factor or intervention on the outcome would be for patients with long-term symptoms, and for the government to offer new types of healthcare services to improve the outcome. The rating was on a 9-point scale, with scores 0-3 indicating "not very important", 4-6 indicating "important but not critical", and 7-9 indicating "critical" outcomes. Based on this rating, we included outcomes rated as "critical" for both KQs, which included: non-recovery/persistent symptoms; major cardiovascular event or organ impairment; moderate/severe or persistent (≥3 weeks) fatigue, breathlessness/dyspnea, impairment in functional capacity, cognitive impairment, sleep disturbances, pain including headaches and chest pain; important impact on quality of life; clinical/pathological levels of psychopathology (e.g., anxiety, depression, post-traumatic stress disorder); and unable to return to full-time work/school/education or caring role. For KQ2, due to the expectation of scarce evidence we also included outcomes rated as important, including: all-cause hospital admission, emergency department visits, requiring urgent care outside of hospital, requiring referral for specialist care for physical and/or mental health (may include new onset of disease such as diabetes), requiring pulmonary rehabilitation and/or long-term oxygen therapy, and any or serious adverse effects of the intervention/treatment. For KQ1, we included outcomes assessed at least 12 weeks after Covid-19 diagnosis or symptom onset (including studies where mean follow-up duration ± 1 standard deviation was ≥12 weeks). For KQ2, the post-baseline follow-up had to be at least 3 weeks and outcomes measured ≥12 weeks' post-Covid. If outcomes were assessed during follow-up from an intervention and included <12 week data (e.g., hospitalization during follow-up), we looked for data specific to event timing (e.g., in figures or text) or contacted authors for data on events occurring ≥12 weeks post-Covid.

We included peer-reviewed articles, results in trial registrations (if no report published yet), and pre-prints of primary studies, including (for KQ1) prospective/retrospective observational studies with ≥ 300 participants with Covid-19, and (for KQ2) randomized and quasi-randomized or experimental studies (e.g., controlled before-after, interrupted time series, uncontrolled before-after implementation studies), . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) For all non-randomized studies, we prioritized multivariable adjusted data (or other similar adjustment methods, i.e., matching/stratification) where at least age, sex (when applicable), some measure of Covid-19 illness severity (e.g., hospitalization, ICU admission, etc.), and comorbidities were taken into account.

For KQ1, we included studies with adjustment for at least two of the four variables, whereas for KQ2 we included all studies regardless of adjustment.

The search strategies for each KQ (Supplement) were developed by a research librarian and peerreviewed by a second librarian using the PRESS 2015 checklist (29) . Concepts related to post Covid-19

were combined with concepts related to risk factors (KQ1) and interventions (KQ2). Search vocabulary and syntax were adjusted across databases. In order to facilitate search updates, the searches were conducted in Ovid using a multifile search for Medline® including Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Embase. We limited the search to studies in English or French from any country/setting, published from January 2021 (KQ1) and June 2020 (KQ2) onwards. The date limit was applied given the timeline of Covid-19 emergence and our focus on long-term outcomes, and (for KQ1) because we had access to other reviews from which to locate studies published earlier (12, 13, 30) .

Moreover, our earlier review on risk factors associated with Covid-19 severity (including long-term outcomes) with literature search updated in April 2021, did not identify any studies prior to Fall 2020 (26) . These searches were run on August 12, 2021 (KQ1) and July 28, 2021 (KQ2 Search results were uploaded to an EndNote library (v. X9, Clarivate Analytics, Philadelphia, PA), duplicates were removed, and then were exported to DistillerSR (https://www.evidencepartners.com/).

Following the pre-defined eligibility criteria, a two-step study selection was done in DistillerSR, first by title-abstract (screening) and then by full-text (selection). Before each step, all reviewers involved in study selection piloted a random sample of records to resolve any ambiguousness. During screening, we . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 25, 2022. ;  https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint applied the liberal accelerated method whereby each title-abstract requires one reviewer to include but two to exclude. Any potentially relevant record was retained for full-text review. Study selection was done in duplicate (i.e., two independent reviewers) with arbitration by a third reviewer in case of a disagreement. If additional information was required to make a final decision on a study, we contacted the corresponding author twice via e-mail over two weeks. We excluded the study if there was no response after the two attempts. We documented the screening process in a PRISMA flow-diagram and recorded the reasons for all full-text exclusions.

We developed standardized data extraction forms in Excel. After piloting the form, one reviewer extracted data from the included studies independently and a second reviewer verified all data for accuracy and completeness. Disagreements were resolved by discussion or by consulting a third reviewer.

From each study, we extracted information related to: study characteristics, population characteristics, setting and type of care during acute phase, risk factors (KQ1) or intervention characteristics (KQ2) and comparators, follow-up length, analysis details, outcome definitions and ascertainment, and results data.

For all outcomes we prioritized including dichotomous (e.g., proportion with event or important degree of dysfunction) over continuous (e.g., mean score) data, and data attributed to or changed since Covid-19 (e.g., change in outcome pre versus post-Covid). We also prioritized outcomes assessed using a valid measurement tool/scale that best represented the outcome domain (23) and did not include those based on single question about experiencing a symptom unless it indicated the symptoms were persistent/moderate/severe. In cases of missing or unclear information, we contacted the study authors for clarification, and ceased contact after two attempts if we received no response. In case of multiple analyses reported for an outcome in observational studies, we extracted the most adjusted data. If data for outcomes at multiple time points were reported we selected the data closest to 12 and 24 months, with a preference for longer versus shorter time. We converted continuous to binary data where possible, to enable a pooled estimate across several studies (23) .

We assessed risk of bias of included studies using the JBI critical appraisal checklist for cohort studies (31) (KQ1), Cochrane RoB 2.0 for randomized studies (32) and JBI critical appraisal checklist (quasiexperimental) for quasi-randomized and other experimental studies, such as controlled before-after studies (31) (KQ2). For all study designs, we added a question about Covid-19 ascertainment (domain considered as low risk if ≥90% were lab-confirmed). For KQ1, we collected information about missing . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint outcome data (i.e., measured as per methods but no results reported), and for KQ2 observational studies, we added three additional questions about selective reporting, missing outcome data, and whether a sufficient amount of eligible patients (>50%) were enrolled. The overall risk of bias for an outcome was considered "low" if all domains were at low risk of bias, of "some concern" if fewer than two domains were at high risk of bias and we did not feel the study conclusions would be impacted by that domain (e.g., ascertainment of exposure), and "high" if ≥2 domains were assessed as being high risk.

After piloting each tool on a sample of studies, one reviewer assessed the quality of each study independently, followed by verification by a second reviewer. Disagreements were resolved by discussion or arbitration by a third reviewer, if needed. To inform our assessment, we used information from all publications associated with any study as well as trial registrations and protocols for KQ2 studies. We did not exclude studies due to high risk of bias, however, risk of bias was considered when assessing the certainty of evidence using the Grading of Recommendations, Assessment, Development and Evaluation approach (GRADE).

For both KQs, we charted the study data in terms of the main variables of intervention/exposure, Covid-19 illness severity (hospitalized, mixed, non-hospitalized), timing of outcome measurement, and outcome.

As pre-specified, we considered a meta-analysis if there was enough clinical and methodological similarity in an exposure-outcome comparison and data for that comparison was available in at least 75% of the studies. For the risk factors related to acute-phase illness severity (e.g., critical/severe illness vs. not), with the exception of need for hospitalization which was only analyzed in mixed populations, we analyzed data separately for hospitalized, mixed severity and non-hospitalized populations to avoid confounding. Although acute Covid-19 severity was defined using different standards across the studies, For KQ1 and studies with a control group in KQ2, we planned to use a pairwise random-effects metaanalysis. We employed a generic inverse variance method for KQ1 because of the preference for using relative measures from adjusted analysis. For all syntheses whether or not from meta-analysis, we categorized findings by magnitude: a relative effect/association of 0.75 to 1.49 was considered as "littleto-no", whereas 0.50 to 0.74 and 1.5 to 1.99 were "small-to-moderate" and <0.50 or ≥2.00 were "large" effects/associations for fewer/benefit or more/harm, respectively. In absence of a meta-analysis, consensus was made on a best estimate (within one of these categories) of effect/association across . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint studies while considering their relative weight by sample size. As pre-defined, we considered several variables for either grouping studies or conducting subgroup analyses if substantial heterogeneity existed in magnitude (e.g., different categories of conclusions) or direction of association/effects, including hospitalized versus non-hospitalized/mixed population, lab-confirmed Covid-19 versus otherwise, timing of outcome assessment (e.g., 12-22 weeks versus ≥22 weeks), symptom severity for both KQs as well as components of the intervention for KQ2 (e.g., enrollment in acute versus post-acute phase, online versus in-person intervention, follow-up timing). We also conducted sensitivity analysis by removing studies having high risk of bias, particularly those in KQ1 that only sufficiently reported univariate analyses despite conducting multivariate analysis. We would have tested for small study effects using funnel plots and Egger's regression test if an analysis included at least 10 studies.

The certainty of evidence for each exposure-outcome association across the studies was assessed by at least two reviewers using GRADE (33, 34) . We assessed our certainty in the categorical conclusions about the magnitude of association/effect as described above, though if an association had higher certainty at a smaller magnitude (small-to-moderate vs. large association) we chose to report the higher certainty magnitude. For observational studies, we started at high certainty for KQ1 (35) and low certainty for KQ2 (28) . For randomized and non-randomized trials in KQ2, we started at high certainty.

We rated down the certainty for concerns related to risk of bias, indirectness (mainly in terms of whether reported outcome measures were a good conceptual match to our outcomes of interest), inconsistency (in direction and/or magnitude of effect) across the studies or lack of consistency (single studies), imprecision (95% confidence intervals indicating the effect/association may allow for more than one conclusion e.g. little-to-no and a small-to-moderate association), and/or reporting bias domains by one or two levels depending on how serious the concerns were, that is how much overall conclusions appear to be impacted by the domain. The final certainty of evidence (i.e., high, moderate, low, very low) and the reasoning for each are presented in summary tables.

We identified 4,612 records from searching databases and 150 records from other sources; 17 unique records met the eligibility criteria and were included (Figure 1 ; see Supplement for the lists of excluded studies for KQs 1 and 2) (4, [14] [15] [16] [17] [18] [19] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] . Study characteristics are included in Table 1 and Table S3 .

The studies originated from China (n=5), Italy (n=2), Norway (n=2), Russia (n=2), Switzerland (n=2), and one each from the UK, USA, Sweden, and Turkey. Fourteen studies were classified as prospective . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 25, 2022. and three as retrospective cohort studies. The studies included a median of 540 participants (range: 304-11,955), with lab-confirmed Covid-19 in majority of studies (n=13), and varying baseline Covid-19 severity (hospitalized n=9, non-hospitalized n=3, mixed severity n=5). Of the included studies, only one was exclusively in children (40) . The median age in other studies was 53.0 years (range: 42.7-69.0) and the median male proportion across the studies was 49%. Most of the studies (n=12) were assessed as having some concern for risk of bias, mainly due to issues arising from incomplete follow-up data, insufficient statistical adjustment (e.g., results not adjusted for comorbidities or illness severity), or outcome/exposure assessment method (i.e., self-reported outcomes or not measured with valid tools) ( Table S4) . Only one study (37) was assessed as having low risk of bias, which included elderly people previously hospitalized with Covid-19.

The certainty of evidence was downgraded for all risk factor-outcome associations, mostly due to concerns related to risk of bias, inconsistency (i.e., single study or inconsistent findings across studies), and/or indirectness (e.g., reported outcomes not aligning with review question). Table 2 summarizes the findings where the evidence was of low or greater certainty; Tables S5-S8 contain more detail including individual study and meta-analysis results, including risk factors for which there was very low certainty.

The certainty of evidence was moderate for a small-to-moderate association between female sex and higher: non-recovery (8 studies, n=6,613) (15-18, 38, 39, 41, 43) , fatigue (8 studies, n=7,116) (14, 15, 17, 36, 38, 39, 43, 44) , and dyspnea (4 studies, n=3,817) (15, 17, 38, 39) . The certainty of evidence was low for a small-to-moderate association with higher: non-recovery among children aged ≥6 versus <2 years (1 study, n=518) (40), functional incapacity in hospitalized adults aged ≥60 versus <60 years old (2 studies, n=867) (15, 42) , functional incapacity in females (2 studies, n=867) (15, 42) , and lower return to work (at a median of 6.7 months from symptom onset) in non-White people (1 study, n=382) (19) . Several findings had low certainty for little-to-no association, and several risk factors had very low certainty evidence (Table S5) .

The certainty of evidence was low for a small-to-moderate association between: number of comorbidities (i.e., ≥1 versus 0) and non-recovery (4 studies, n=2,069) (4, (15) (16) (17) , chronic pulmonary disease with fatigue (2 studies, n= 2,961) (36, 38) , rheumatologic disorder with depression/anxiety (1 study, n=2,649) (38) , and chronic obstructive pulmonary disease (COPD) or hypertension with cognitive impairment (1 study, n=1,539) (37) . Post Covid-19 condition was found to have little-to-no association (low certainty)

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint with a few other pre-existing conditions, including diabetes and cardiovascular diseases, and there was very low certainty for several other pre-existing conditions (Table S6) .

Severe or critical acute Covid-19 illness severity (versus not) showed a moderate certainty of evidence for a large association with cognitive impairment (hospitalized populations; 2 studies, n=2,335) (37, 43) , small-to-moderate association with non-recovery (mixed-severity populations; 2 studies, n=1,438) (4, 17) , and little-to-no association with dyspnea (hospitalized populations; 2 studies, n=2,976) (15, 38) . There was a low certainty of evidence for a large association between hospitalization during the acute phase with: non-recovery (1 study, n=1,007) (4), more dyspnea (1 study, n=431) (17) , and reduced return to work (1 study, n=11,955) (45) .

The certainty of evidence was low for a small-to-moderate association between ≥1 versus 0 acute Covid-19 symptoms (1 study, n=599)(18) and ≥3 versus ≤2 symptoms (1 study, n=304) (16) with non-recovery.

A small-to-moderate association with low certainty was also found between: number of acute Covid-19

symptoms and fatigue (1 study, n=458) (44), severe or critical acute Covid-19 severity (versus not) and depression (2 studies, n=4,382) (14, 38) , and need for intubation and functional incapacity (1 study, n=382) (19) . Table S7 includes detailed findings by study and synthesis.

We identified 3,595 records from searching databases and 186 records from other sources; 18 unique records, including 8 studies identified through the KQ1 search, met the eligibility criteria and were included (Figure 1 ; Tables 1 and S9) (14, 19, 36, 41, (46) (47) (48) (49) (50) (51) (52) (53) (54) (55) (56) (57) (58) (59) . Most of the studies originated from China (n=7); others were from USA (n=3), Italy (n=2), and one each from India, Iran, Belgium, Norway, Spain and Switzerland. Nine studies were classified as retrospective controlled cohorts; others were prospective (controlled/uncontrolled) cohorts (n=6), non-randomized experimental (n=2) and a pilot randomized controlled trial (56) . The studies included a median of 82 participants (range: 10-538) with 100% labconformed Covid-19 in majority of studies (n=14). Only one study involved hospitalized and homeisolated participants (36), while the other 17 studies were among hospitalized individuals with mixed severity (ranging from being asymptomatic to severe/critical). We assessed the risk of bias for objective (i.e., measured) and subjective (i.e., self-reported) outcomes separately; none of the studies were rated as having low risk of bias across all outcomes (Tables S10-S12). The only randomized study identified was a pilot trial with 10 participants (56) that had concerns in several domains related to randomization, blinding, outcome measurement, and reporting the findings. The most common sources of potential bias . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint in other non-randomized studies (experimental and cohort) were related to unreliable outcome measurement, incomplete follow-up, and not accounting for confounding factors.

Interventions identified as potentially preventing post Covid-19 condition included standard medication (14, 19, 36, 41, 47, 50, (56) (57) (58) (59) , traditional/ayurvedic medication (52, 53) , stem cell therapy (49), rehabilitation or similar therapies (46, 51, 54) , and screening and referrals (48, 55) . We grouped interventions by timing, as those implemented during acute (symptom onset to 4 weeks) phase of Covid-19 with outcomes assessed at shorter (12-16 weeks) or longer (>16 weeks) follow-up duration post Covid-19; and interventions implemented during early post-acute (4-8 weeks) phase of Covid-19 with aforementioned shorter and longer follow-up time ( Table 3) .

With the exception of steroids and antibiotics, we identified single studies for all interventions. Across all intervention-outcome comparisons, the certainty of evidence was found to be very low, mainly due to risk of bias, inconsistency/lack of consistency (i.e., single study effect), and in some instances imprecision.

Four studies (n=896) (41, 47, 58, 59) reported on steroid use during the acute phase in hospitalized patients with dyspnea assessed at 12-16 weeks post Covid-19. Two studies (n=675) (19, 36) reported on use of antibiotics during the acute phase in hospitalized and home-isolated participants, with fatigue assessed at ≥6 months after Covid-19 diagnosis. The certainty of evidence for both comparisons was assessed as very low due to serious concerns about risk of bias and inconsistency.

These systematic reviews were conducted in response to the growing recognition of an emerging threat and anticipated burden of post Covid-19 condition.

Most of the findings had low or very low certainty evidence, often due to concerns related to risk for bias and inconsistent findings across the studies (in case of a pooled estimate) or a single study effect, although generally the reported outcomes aligned well with the review question (i.e., no indirectness).

The only risk factors found to have a moderate certainty in their association with more than one post Covid-19 condition outcome were female sex and Covid-19 illness severity during the acute phase. Based on this evidence, being a female is probably (moderate certainty) associated with a small-to-moderate increase in post Covid-19 non-recovery, fatigue and dyspnea, while severe/critical acute Covid-19 (versus not severe/critical) has probably a large association with cognitive impairment (among those who were hospitalized with Covid-19), small-to-moderate association with non-recovery (among mixed . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint populations), and little-to-no association with dyspnea (among those who were hospitalized with Covid-19). Among other risk factors, hospitalization during the acute phase may (low certainty) be associated with a large increase in non-recovery, dyspnea, and reduced return to work. We did not identify a large association for any other risk factor-outcome comparisons.

These findings add considerably to the existing evidence. A recent scientific report by the Belgian Healthcare Knowledge center identified female sex and level of care received during acute Covid-19 as potential risk factors for long-term outcomes following Covid-19 (60) . The report was limited to studies conducted in Europe and the USA with symptoms reported at ≥4 weeks after the disease onset. Our review additionally involves a formal data synthesis and assessment of evidence certainty which were not included in the Belgian report. Findings from a recent rapid review by National Institute for Health and Care Excellence (NICE) also indicate that female sex and severity of acute Covid-19 illness (i.e., hospitalization, ICU admission) increase the risk of developing persistent symptoms after initial Covid-19 infection (30). Our certainty for these findings was higher, possibly because we restricted inclusion to higher quality studies (having adjustment) and followed more rigorous methods for study selection and data synthesis. Our findings are also supported by a rapid review of risk factors associated with chronic Covid-19 symptoms, undertaken by Alberta Health Services (AHS) (61) . In their review, among multiple risk factors identified as having a significant association with post Covid-19 condition were female sex in previously hospitalized Covid-19 patients, and hospitalization and ICU admission in non-hospitalized and hospitalized populations, respectively. The findings in the AHS rapid review were based on statistical significance, while in our review we relied on the magnitude of association and its certainty using various criteria since lack of a statistical significance should not be taken as a lack of association (62) . Compared with the AHS review, we limited outcomes to 30 days or beyond the date of Covid-19 diagnosis and employed a strict population size criterion for eligibility. Despite methodological variation across these reviews and timing of outcome assessment, findings support that there is probably a link between these risk factors and post Covid-19 outcomes. While the association between acute Covid-19 severity and persistent symptoms is plausible, it is yet not clear why females are at a higher risk of post Covid-19

condition. It has been suggested that this could be due to the likely effect of initial exposure as females are more commonly involved in industries that may have a greater exposure to the Covid-19 virus (e.g., healthcare, teaching) (63). Nonetheless, more research needs to be conducted to further establish these associations.

The certainty of evidence for individual pre-existing conditions was low or very low, and most of the evidence was for little-to-no association. Although existing evidence indicates older age might increase . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 61, 64, 65) , most of our evidence was low certainty for little-to-no association apart from more functional incapacity in ≥60 versus <60 year old hospitalized patients. Our findings may differ from other reviews due to our strict eligibility criteria as we only included studies reporting outcomes at least 12 weeks after disease onset, to minimize the likelihood of symptoms associated with acute Covid-19, with at least 300 participants, and controlling for a minimum set of confounders (i.e., 2 or more of age, sex, comorbidities, and illness severity). Also, we excluded studies where all participants were admitted to an ICU to avoid overlapping of post Covid-19 condition with post-intensive care syndrome, which is characterized by similar features to post Covid-19 (66) .

Our findings are mostly applicable to longer-term consequences of Covid-19 occurring ≥22 weeks after diagnosis or illness onset as we identified only a few studies with shorter follow-up length. Also, despite the large volume of data emerging, many studies came from a hospitalized population. Of all the included studies, we identified only one that was exclusively in children who were previously hospitalized with Covid-19 (40) . The study reported on several potential risk factors including age, sex, acute Covid-19 severity, obesity, and allergic diseases, however, none were identified as having a strong association with outcomes of our review. Evidence was also sparse in relation to pre-existing socioeconomic variables (e.g., race/ethnicity, income, education, employment) and marginalized groups including indigenous communities, institutionalized populations, and persons with disability, despite being listed as priority populations for Covid-19 policies by several jurisdictions. Similarly, we did not locate studies reporting on associations between Covid-19 vaccination status and long-term consequences of Covid-19. Moreover, current studies are mostly based on self-reported outcome and exposure data, which could be subject to recall bias and misclassification, and may limit generalizability of the evidence to other populations (30).

There is also the possibility of over/under-estimation of the reported associations as people from certain populations may be under-represented in primary studies (67) . Further, based on the current literature, it is still challenging to determine if persistent symptoms are actually attributed to initial Covid-19 or would have occurred independent of the infection (60). To overcome these limitations, more robust evidence of risk factors is required particularly in non-hospitalized populations and community settings. Use of administrative data and establishing universal outcome definitions and assessment methods could ensure robustness of the evidence.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (68) . Thus, continuous review and assessment of the rapidly emerging evidence is important to better shape our understanding as the body of evidence grows.

We followed established guidelines for systematic reviews to provide methodologically rigorous syntheses of the available evidence on risk factors associated with post Covid-19 conditions and potentially preventive interventions. The review questions and outcomes were informed by input from clinical experts, stakeholders, and a patient panel. A wide range of risk factors and preventive interventions were considered in our reviews. Our findings are based on our certainty about associations/magnitudes of effect reaching predefined thresholds, which is informed by several factors, rather than reliance of statistical significance that is commonly used across the literature. 

Covid-19 non-recovery, fatigue and dyspnea, and having a severe or critical acute Covid-19 illness (versus not severe/critical) probably has a large (2-fold or more) association with increased cognitive impairment, a small-to-moderate association with more non-recovery, and little-to-no association with dyspnea. Though with low certainty, hospitalization during the acute phase may have large associations with more non-recovery and dyspnea and less return to work. All other evidence on risk factors was low or very low certainty. Evidence on possible preventive interventions was mostly in hospitalized patients and observational in nature, and all provided very low certainty evidence. Continuous assessment of the rapidly emerging evidence is important to better shape our understanding as the body of evidence grows.

Sufficiently powered prospective trials of preventive interventions are warranted.

Post Covid-19 condition is becoming a public health challenge for many communities and governments.

To be effective and efficient, public health policies and programs that will be rolled out in response to this challenge need careful evaluation and assessment of available resources. Synthesizing high-quality evidence to identify risk factors of persistent Covid-19 symptoms and possible preventive interventions is therefore important in highlighting areas where policy-makers can take action to mitigate the longer term outcomes of this pandemic. The wide range of post Covid-19 condition outcomes and associated risk factors emphasize the need for a coordinated multidisciplinary approach to assessment and management strategies. We found that females and people with severe or critical acute-phase Covid-19 are at greater risk of developing post-Covid complications. These findings imply that public health guidelines in relation to surveillance, screening services, and other services such as, access to sickness and disability benefits, might need to prioritize these groups. Interventions targeting fatigue, dyspnea, and cognitive impairment (especially in those with previous severe illness) may be good to prioritize for development . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 25, 2022 and evaluation and to provide evidence on their effects. Further, inputs from patients and primary care providers should be taken into account when developing new care pathways and appropriate services, including long-term follow-up, rehabilitation and support groups, to ensure management and treatment strategies are tailored to patient needs and the disease manifestations.

Contributors: JP and LH designed the study. SR, SG and AW screened citations for inclusion and were involved in data extraction and interpretation. JP, SR, SG and AW were involved is risk of bias assessments. All authors were involved in interpretation of the data. JP wrote the draft manuscript with input from all authors. All authors approved the final version of the manuscript. JP is the guarantors of this manuscript and accepts full responsibility for the work and the conduct of the study, had access to the data, and controlled the decision to publish. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. [University Health Network/Sinai Health System]) for their assistance with scoping the review, review of the protocol, and rating the outcomes, and the PHAC post Covid-19 condition patient panel (Jonah McGarva, Ruth Castellanos, Nicole Keefler, Tracey Thompson, Susan Goulding) for rating the outcomes. Alejandra Jaramillo Garcia, Francesca Reyes Domingo, and Naomi Tschirhart provided input on a draft version of this manuscript. We also thank information specialists Kate Merucci and Lynda Gamble (Health Canada) for conducting the database searches, Robyn Hocking (Health Canada) and Tara Landry (University of Alberta) for peer review), and Carolyn Spry and Nina Frey (CADTH) for conducting the grey literature search.

The Public Health Agency of Canada (PHAC) funded this work. The funder had no role in the conduct of this research, nor did it decide whether or not to publish the results.

Distinguished Researcher with the Stollery Science Lab supported by the Stollery Children's Hospital Foundation.

Ethics approval: This research did not involve human research participants and thus did not require ethics approval.

The lead author of this work, JP, affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as originally planned in the protocol have been explained.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted March 25, 2022. ; https://doi.org/10.1101/2022.03.25.22272949 doi: medRxiv preprint Data sharing: All of the data extracted for this review are included in the manuscript and associated supplementary files.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Prospective controlled cohort (14) Retrospective controlled cohort (3) Pilot RCT (1) Non-randomized experimental design (2) Prospective controlled cohort (2) Prospective uncontrolled cohort (4) Retrospective controlled cohort* (9) Country (n)

China (5) Italy (2) Norw ay (2) Russia (2) Sw itzerland (2) USA (1) UK (1) Sw eden (1) Turkey (1) China (7) USA (3) Italy (2) India (1) Iran (1) Belgium ( 

≥90% lab-confirmed (12) <90% lab confirmed (2) NR (1) ≥90% lab confirmed (12) <90% lab confirmed (1) NR (5) Baseline Covid-19 severity (n) Hospitalized (9) Mixed severity ǂ (5) Non-hospitalized (3) Hospitalized (17) Mixed severity (1)

≥22 w eeks (14) 12-16 w eeks (12) >16 w eeks (6)

Some concerns (11) High (5) Low (1) Some concerns (6) High (12) Low (0) Abbre viations: NR: not reported; RCT : randomized controlled trial *T hese studies were prospective for the authors' main objective but retrospective for the purposes of this review which analyzed data on treatment(s) received during acute illness. † Excluding the one study that included children (Osmanov et al.) . ǂ Studies including hospitalized and non-hospitalized participants. Non-hospitalized (n = 1)

Hospitalized (n = 2) Little-to-no association Low We rated the certainty based on a pooled estimate in case of a meta-analysis or a best estimate of effect/association (relative to the thresholds) across studies based on individual study results considering their sample size and measures of variance in absence of a meta-analysis. Certainty started at high and was rated down by 0, 1, or 2 levels for risk of bias (a), indirectness in outcome (b), inconsistency/lack of consistency (c), and imprecision/ wide confidence intervals (d); capital letters indicates very serious concern. : versus * Assessed using GRADE. Certainty was rated down by 0, 1, or 2 levels for risk of bias (a), indirectness in outcome (b), inconsistency/lack of consistency (c), and imprecision/ wide confidence intervals (d); capital letters indicates very serious concern. T he certainty rating applies similarly to each outcome within each row.

World Health Organization. WHO Coronavirus (COVID-19) Dashboard: WHO

Symptom Duration and Risk Factors for Delayed Return to Usual Health Among Outpatients with COVID-19 in a Multistate Health Care Systems Network -United States

Characterizing long COVID in an international cohort: 7 months of symptoms and their impact

Post-COVID syndrome: A singlecenter questionnaire study on 1007 participants recovered from COVID-19

Centers for Disease Control and Prevention. Post-COVID Conditions

Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline

Facing up to long COVID

Post-acute COVID-19 syndrome

World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus

Long COVID, a comprehensive systematic scoping review

Estimates of the prevalence of self-reported long COVID and associated activity limitation, using UK Coronavirus (COVID-19) Infection Survey data. UK: Office for National Statistics

Prevalence of long-term effects in individuals diagnosed with COVID-19: an updated living systematic review2021

6-month consequences of COVID-19 in patients discharged from hospital: a cohort study

Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol

Long COVID In Adults at 12 Months After Mild-to-Moderate SARS-CoV-2 Infection

Burden of post-COVID-19 syndrome and implications for healthcare service planning: A population-based cohort study

Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients

A prospective study of longterm outcomes among hospitalized COVID-19 patients with and without neurological complications

Research priorities for Long Covid: refined through an international multi-stakeholder forum

Long covid: WHO calls on countries to offer patients more rehabilitation

National Institutes of Health. NIH launches new initiative to study "Long COVID": NIH

Cochrane Handbook for Systematic Reviews of Interventions

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Risk factors associated with severe outcomes of COVID-19: An updated rapid review to inform national guidance on vaccine prioritization in Canada. medRxiv. 2021. 27. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

National Institute for Health and Care Excellence (NICE), Scottish Intercollegiate Guidelines Network (SIGN)

Joanna Briggs Institute Reviewer's Manual: The Joanna Briggs Institute

RoB 2: a revised tool for assessing risk of bias in randomised trials

Rating the certainty in evidence in the absence of a single estimate of effect

Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients

GRADE Guidelines 28: Use of GRADE for the assessment of evidence about prognostic factors: rating certainty in identification of groups of patients with different absolute risks

Long COVID in a prospective cohort of home-isolated patients

Post-infection cognitive impairments in a cohort of elderly patients with COVID-19

Incidence and risk factors for persistent symptoms in adults previously hospitalised for COVID-19

Prevalence of Symptoms More Than Seven Months After Diagnosis of Symptomatic COVID-19 in an Outpatient Setting

Risk factors for long covid in previously hospitalised children using the ISARIC Global follow-up protocol: A prospective cohort study

Diffusion capacity abnormalities for carbon monoxide in patients with COVID-19 at 3-month follow-up

Health-related quality of life of COVID-19 patients after discharge: A multicenter follow-up study

Half-year follow-up of patients recovering from severe COVID-19: Analysis of symptoms and their risk factors

Prevalence and determinants of fatigue after covid-19 in non-hospitalized subjects: A population-based study

Patterns and predictors of sick leave after Covid-19 and long Covid in a national Swedish cohort

The effectiveness of cognitive-motor training on reconstructing cognitive health components in older male adults, recovered from the COVID-19

Medium-term impact of COVID-19 on pulmonary function, functional capacity and quality of life

Impact of peritraumatic dissociation in hospitalized patients with COVID-19 pneumonia: A longitudinal study

Human Umbilical Cord Mesenchymal Stromal Cell Treatment of Severe COVID-19 Patients: A 3-Month Follow-Up Study Following Hospital Discharge

Frequent and Persistent Salivary Gland Ectasia and Oral Disease After COVID-19

Functional outcomes and post-discharge care sought by patients with COVID-19 compared to matched controls after completing inpatient acute rehabilitation

A pilot clinical study of an add-on Ayurvedic formulation containing Tinospora cordifolia and Piper longum in mild to moderate COVID-19

Effects of Chinese Medicine on Symptoms, Syndrome Evolution, and Lung Inflammation Absorption in COVID-19 Convalescent Patients during 84-Day Follow-up after Hospital Discharge: A Prospective Cohort and Nested Case-Control Study

Follow-up of functional exercise capacity in patients with COVID-19: It is improved by telerehabilitation

Long-term outcomes of patients following hospitalization for coronavirus disease 2019: a prospective observational study

Evaluation of Adjunctive Photobiomodulation (PBMT) for COVID-19 Pneumonia via Clinical Status and Pulmonary Severity Indices in a Preliminary Trial

3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study

Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study

Follow-up study of the pulmonary function and related physiological characteristics of COVID-19 survivors three months after recovery

Brussels: Health Services Research (HSR) Brussels: Belgian Health Care Knowledge Centre (KCE)

Rapid Evidence Report: Updated review of prolonged symptoms after acute COVID-19 infection. Alberta: Alberta Health Services

Using Effect Size-or Why the P Value Is Not Enough

Which occupations have the highest potential exposure to the coronavirus (COVID-19)? UK: Office for National Statistics

Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study

Attributes and predictors of long COVID

Clinical review: intensive care unit acquired weakness

A Comparative Analysis of Telephone and In-Person Survey Administration for Public Health Surveillance in Rural American Indian Communities

Rehabilitation and COVID-19: a rapid living systematic review by Cochrane Rehabilitation Field updated as of December 31st, 2020 and synthesis of the scientific literature of 2020

Functional outcome after inpatient rehabilitation in postintensive care unit COVID-19 patients: findings and clinical implications from a real-practice retrospective study

Respiratory rehabilitation in elderly patients with COVID-19: A randomized controlled study

Outcomes of a COVID-19 recovery program for patients hospitalized with SARS-CoV-2 infection in New York City: A prospective cohort study

Preventive effects of Pycnogenol(R) on cardiovascular risk factors (including endothelial function) and microcirculation in subjects recovering from coronavirus disease 2019 (COVID-19)

Pycnogenol(R)-Centellicum(R) supplementation improves lung fibrosis and post-COVID-19 lung healing

Coronavirus (COVID-19) vaccination and self-reported long COVID in the UK

Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study

Six-month sequelae of post-vaccination SARS-CoV-2 infection: a retrospective cohort study of 10,024 breakthrough infections

Association between vaccination status and reported incidence of post-acute COVID-19 symptoms in Israel: a crosssectional study of patients tested between

Symptoms After COVID-19 Vaccination in Patients With Persistent Symptoms After Acute Infection: A Case Series

Change in Symptoms and Immune Response in People with Post-Acute Sequelae of SARS-Cov-2 Infection (<em>PASC</em>) After SARS-Cov-2 Vaccination